Abstract | BACKGROUND: METHODS:
Sham-operated or hypertensive rats were treated with tempol (18 mg.kg(-1)day(-1) or vehicle) for 8 weeks. Systolic blood pressure was monitored weekly. At the end of the treatment, a catheter was inserted into the left carotid artery and into the left ventricle (LV) to assess arterial blood pressure and contractile function. Morphometry of the LV was carried out in hematoxylin/ eosin sections and fibrosis was assessed in picrosirius red-stained sections. Cardiac TGF-β level was evaluated by immunofluorescence. Cardiac MMP-2 levels and activity were determined by gelatin zymography, in situ zymography, and immunofluorescence. Cardiac superoxide production was evaluated by dihydroethidium probe. RESULTS:
Tempol treatment attenuated 2K1C-induced hypertension and reversed the contractile dysfunction in 2K1C rats. Cardiac hypertrophy was ameliorated by antioxidant treatment. Hypertensive rats showed increased cardiac MMP-2 levels, however tempol did not decrease MMP-2 levels. Increased TGF-β level, total gelatinolytic activity and oxidative stress were found in untreated 2K1C rats. Tempol treatment decreased oxidative stress, TGF-β levels, and gelatinolytic activity in 2K1C rats to control levels. CONCLUSIONS:
|
Authors | Elen Rizzi, Michele M Castro, Carla S Ceron, Evandro M Neto-Neves, Cibele M Prado, Marcos A Rossi, Jose E Tanus-Santos, Raquel F Gerlach |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 165
Issue 1
Pg. 165-73
(Apr 30 2013)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 21917342
(Publication Type: Journal Article)
|
Copyright | Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Antioxidants
- Cardiotonic Agents
- Cyclic N-Oxides
- Matrix Metalloproteinase Inhibitors
- Spin Labels
- Transforming Growth Factor beta
- Matrix Metalloproteinases
- tempol
|
Topics |
- Animals
- Antioxidants
(pharmacology, therapeutic use)
- Cardiomegaly
(metabolism, pathology, prevention & control)
- Cardiotonic Agents
(pharmacology, therapeutic use)
- Cyclic N-Oxides
(pharmacology, therapeutic use)
- Hypertension
(metabolism, pathology, prevention & control)
- Male
- Matrix Metalloproteinase Inhibitors
(pharmacology, therapeutic use)
- Matrix Metalloproteinases
(biosynthesis, metabolism)
- Rats
- Rats, Wistar
- Spin Labels
- Transforming Growth Factor beta
(antagonists & inhibitors, biosynthesis)
- Up-Regulation
(drug effects, physiology)
|